Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ouvry

Showing results (151-160 of 159) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 159 results.
Bioorganic & Medicinal Chemistry Letters|October 18, 2015
Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancersBernard Barlaam, Sabina Cosulich, Bénédicte Delouvrié, et al.
Journal of Medicinal Chemistry|August 17, 2016
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153)Robert H Bradbury, Rowena Callis, Gregory R Carr, et al.
Bioorganic & Medicinal Chemistry Letters|March 10, 2017
Identification of novel TACE inhibitors compatible with topical applicationGilles Ouvry, Yaël Berton, Yushma Bhurruth-Alcor, et al.
Bioorganic & Medicinal Chemistry Letters|March 25, 2018
Sulfoximines as potent RORγ inverse agonistsGilles Ouvry, Franck Bihl, Claire Bouix-Peter, et al.
Journal of Medicinal Chemistry|April 24, 2018
The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one)Kurt G Pike, Bernard Barlaam, Elaine Cadogan, et al.
Bioorganic & Medicinal Chemistry|August 19, 2017
Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasisJean-Guy Boiteau, Gilles Ouvry, Jean-Marie Arlabosse, et al.
Chemmedchem|January 13, 2018
Discovery and Characterization of CD12681, a Potent RORγ Inverse Agonist, Preclinical Candidate for the Topical Treatment of PsoriasisGilles Ouvry, Nicolas Atrux-Tallau, Franck Bihl, et al.
Scientific Data|August 4, 2023
EUSEDcollab: a network of data from European catchments to monitor net soil erosion by waterFrancis Matthews, Gert Verstraeten, Pasquale Borrelli, et al.
The American Journal of Gastroenterology|August 16, 2017
Dramatic Increase in Incidence of Ulcerative Colitis and Crohn's Disease (1988-2011): A Population-Based Study of French AdolescentsSilvia Ghione, Hélène Sarter, Mathurin Fumery, et al.
Pageof 16

Showing results (151-160 of 159) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 159 results.
Bioorganic & Medicinal Chemistry Letters|October 18, 2015
Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancersBernard Barlaam, Sabina Cosulich, Bénédicte Delouvrié, et al.
Journal of Medicinal Chemistry|August 17, 2016
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153)Robert H Bradbury, Rowena Callis, Gregory R Carr, et al.
Bioorganic & Medicinal Chemistry Letters|March 10, 2017
Identification of novel TACE inhibitors compatible with topical applicationGilles Ouvry, Yaël Berton, Yushma Bhurruth-Alcor, et al.
Bioorganic & Medicinal Chemistry Letters|March 25, 2018
Sulfoximines as potent RORγ inverse agonistsGilles Ouvry, Franck Bihl, Claire Bouix-Peter, et al.
Journal of Medicinal Chemistry|April 24, 2018
The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one)Kurt G Pike, Bernard Barlaam, Elaine Cadogan, et al.
Bioorganic & Medicinal Chemistry|August 19, 2017
Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasisJean-Guy Boiteau, Gilles Ouvry, Jean-Marie Arlabosse, et al.
Chemmedchem|January 13, 2018
Discovery and Characterization of CD12681, a Potent RORγ Inverse Agonist, Preclinical Candidate for the Topical Treatment of PsoriasisGilles Ouvry, Nicolas Atrux-Tallau, Franck Bihl, et al.
Scientific Data|August 4, 2023
EUSEDcollab: a network of data from European catchments to monitor net soil erosion by waterFrancis Matthews, Gert Verstraeten, Pasquale Borrelli, et al.
The American Journal of Gastroenterology|August 16, 2017
Dramatic Increase in Incidence of Ulcerative Colitis and Crohn's Disease (1988-2011): A Population-Based Study of French AdolescentsSilvia Ghione, Hélène Sarter, Mathurin Fumery, et al.
Pageof 16